Pilocarpine
Pilocarpine 1%, 2%, 4% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop of 1%, 2%, or 4% up to four times daily; start pilocarpine-naive patients on 1%
Acute angle-closure glaucoma
1 drop of 1% or 2% up to three times over a 30-minute period; 1 drop of 4% before laser iridoplasty or iridotomy, then 1 drop of 1% four times daily after iridoplasty until an iridotomy can be performed
Prevention of postoperative IOP elevation associated with laser surgery
1 drop of 1%, 2%, or 4%, or two drops administered five minutes apart, 15 to 60 minutes before surgery
Induction of miosis
1 drop of 1%, 2%, or 4%, or two drops five minutes apart; in children before goniotomy or trabeculotomy, 1 drop of 1% or 2% 15 to 60 minutes before surgery
OFF-LABELNot in the FDA label for this product
Adie tonic pupil, dilute pilocarpine test
one instillation of 0.0625% or 0.125%, prepared by dilution since neither is marketed, with the pupil measured 30 to 40 minutes later
Case-control · n=117
In a retrospective case-control study of 117 subjects, 56 with unilateral Adie tonic pupil and 61 controls with unilateral dilated pupils of other cause, 0.0625% discriminated better than 0.125% (area under the ROC curve 0.954 versus 0.840, P = 0.047). With 0.0625%, a change in maximal pupil diameter of at least 0.5 mm on dynamic pupillometry was 100% sensitive and 82.8% specific.
Contraindications
None.
Ophthalmic solution, 1% (15 mL), 2% (15 mL), 4% (15 mL)
Direct acting muscarinic cholinergic agonist that contracts the ciliary muscle, putting tension on the scleral spur and opening trabecular meshwork spaces so outflow resistance falls and IOP drops. Contraction of the iris sphincter produces miosis, which relieves appositional angle narrowing and closure and lowers IOP in certain types of angle-closure glaucoma.
Warnings & Precautions
- Poor illumination: Caution with night driving and hazardous occupations in poor illumination; miotics may also cause accommodative spasm, and patients should not drive or use machinery while vision is not clear.
- Retinal detachment: As with all miotics, rare cases have been reported in certain susceptible individuals and those with pre-existing retinal disease, so a thorough examination of the retina including funduscopy is advised in all patients before starting therapy.
- Iritis: Not recommended for use when iritis is present.
- Paradoxical increase in IOP: Caution is advised in pediatric patients with primary congenital glaucoma because cases of a paradoxical increase in IOP have been reported, and use is not recommended in pediatric glaucoma secondary to anterior segment dysgenesis or uveitis, especially active uveitis.
- Acute angle-closure sequence: Secretory suppressants and hyperosmotic agents may be needed first to lower IOP below 50 mmHg and relieve iris ischemia.
- Contact lens wear: Lenses should be removed before instillation and reinserted no sooner than 10 minutes after dosing.
- Systemic exposure: Punctal occlusion for 2 minutes after instillation limits systemic exposure, and other topical ophthalmic drugs should be separated by at least 5 minutes.
Common Side Effects
The most frequently reported adverse reactions, occurring in 5% or more of patients in the pilocarpine 2% populations of four controlled trials of 90 days to 2 years in 317 patients, were headache or browache, accommodative change, blurred vision, eye irritation, visual impairment described as dim, dark, or jumping vision, and eye pain. The adverse reaction profile in pediatric patients is comparable to that seen in adults. Systemic toxicity after topical ocular dosing is rare, but occasionally sensitive patients may develop sweating and gastrointestinal overactivity at the suggested dosage, and overdosage can produce sweating, salivation, nausea, tremors, slowing of the pulse, and a decrease in blood pressure.
Pregnancy: Category C; animal reproduction studies have not been conducted and fetal harm potential is unknown, so give only if clearly needed.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman.
Safety and effectiveness established; children under 2 years are dosed at 1% three times daily.